Generic Zantac implicated a voluntary recall in cancer

A popular drug to fight heartburn can be linked to cancer and cause a voluntary recall of the product.

The U.S. Food and Drug Administration (FDA) statement is for a voluntary recall of generic versions of Zantac, a heartburn drug that is served in tablet form. The need for recall arises from the presence of N-nitrosodimethylamine (NDMA).

There is no current recall for the "Zantac brand," although the FDA is currently testing it.

According to the World Health Organization, NDMA is listed "as likely to be carcinogenic to humans." This has earned it a Group B2 rating from the Environmental Protection Agency, which means "There is insufficient evidence that it can cause cancer in humans, but for now it is far from conclusive."

However, the FDA notice is aware that "Consumers taking OTC ranitidine may consider using other OTC products approved for their condition." These generic versions of ranitidine tablets are distributed on Walgreens, Walmart and Rite Aid. [1[ads1]9659006] Ticker Security Last Change % Chg WMT WALMART INC. 118.45 +0.15 + 0.13% WBA [19659012] WALGREENS BOOTS ALLIANCE INC. 54.41 +053 + 0.61% RAD RITE AID 7.28 -0.55 -7.02 %

According to the FDA, not all ranitidine medications are part of this recall, and during its release, the FDA also announced that they "do not recommend individuals to stop taking all ranitidine medications at this time." Consumers are advised to consult health professionals to continue the wisest course of action.